Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Analyse van circulerend tumor-DNA bij patiënten met ‘ALK’-positieve longkanker
dec 2019 | Longoncologie